DEF: Zymeworks Sets 2025 Annual Meeting Agenda, Board Elections

Zymeworks Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on December 30, 2025, focusing on director elections, executive compensation, and auditor ratification, alongside reporting 2024 financial and operational highlights.

Summary

• The 2025 Annual Meeting of Stockholders will be held virtually on December 30, 2025, at 9:00 a.m. Pacific Time.
• Stockholders will vote on the election of three Class I directors (Carlos Campoy, Alessandra Cesano, Robert E. Landry) to hold office until the 2028 annual meeting.
• An advisory vote on the compensation of named executive officers will take place.
• The appointment of KPMG LLP as auditors for the year ending December 31, 2025, will be ratified.
• The company reported $76.3 million in total revenue and a net loss of $122.7 million for the year ended December 31, 2024.
• Cash, cash equivalents, and marketable securities totaled $324.2 million as of December 31, 2024.
• Key 2024 preclinical and clinical development highlights include FDA accelerated approval of Ziihera (zanidatamab-hrii) for HER2+ BTC via partner Jazz Pharmaceuticals, initiation of first-in-human global studies for ZW191, and announcement of IND candidate ZW251.
• Overall 2024 corporate goals were achieved at a 91.5% level, with strong performance in R&D and corporate culture, but underperformance in financing and partnerships.
• Several director resignations occurred effective November 6, 2025, including Dr. Nancy Davidson, Dr. Neil Gallagher, and Mr. Derek Miller.
• New directors appointed in 2024 and 2025 include Dr. Alessandra Cesano, Mr. Scott Platshon, Mr. Oleg Nodelman, Mr. Gregory A. Ciongoli, and Mr. Robert E. Landry.
• The research and development committee was dissolved effective November 6, 2025.
• Stock ownership guidelines for non-management directors were adopted in September 2025, requiring beneficial ownership of at least 10,000 shares by September 2028.

Sentiment

Score: 5

Explanation: The filing presents a mixed bag of operational successes (drug approvals, pipeline advancement) and financial challenges (net loss, missed financing goals). Corporate governance updates are positive, but the legal issue with a major shareholder/director adds a negative element. The overall sentiment is neutral to slightly negative due to the financial loss and missed financing targets, balanced by clinical progress.

Positives

• FDA accelerated approval of Ziihera (zanidatamab-hrii) for previously-treated, unresectable or metastatic HER2-positive biliary tract cancer, achieved through the Jazz Pharmaceuticals partnership.
• Initiation of first-in-human global studies for ZW191, an antibody-drug conjugate targeting folate receptor-a, expanding the clinical pipeline.
• Announcement of investigational new drug application candidate ZW251, a glypican-3 targeted antibody drug conjugate, demonstrating continued preclinical pipeline advancement.
• Achieved 91.5% of overall 2024 corporate goals, indicating strong operational performance in research and development and corporate culture objectives.
• Received 93.33% stockholder support for named executive officer compensation in the 2024 advisory vote, reflecting confidence in compensation practices.
• Adopted stock ownership guidelines for non-management directors, requiring 10,000 shares by September 2028, to further align director interests with long-term stockholder value.
• Maintained $324.2 million in cash, cash equivalents, and marketable securities as of December 31, 2024.

Negatives

• Reported a net loss of $122.7 million for the year ended December 31, 2024.
• Did not achieve 2024 corporate goals related to financing and partnerships, citing changes in the competitive landscape and financial markets.
• Oleg Nodelman, a current director, and EcoR1 Capital LLC, a principal stockholder, were fined 3.0 million and 7.0 million Euros, respectively, by the French financial markets regulator (AMF) for market abuse regulations and reporting obligations violations.
• Three directors (Dr. Nancy Davidson, Dr. Neil Gallagher, and Mr. Derek Miller) submitted resignations from the Board of Directors, effective November 6, 2025.
• Only one out of eleven then-members of the Board of Directors attended the 2024 annual meeting of stockholders.

Risks

• Risks and exposures associated with cybersecurity, information security, and data privacy matters, which are overseen by the audit committee.
• Potential impact of the AMF's market abuse and reporting violations fine on Oleg Nodelman and EcoR1 Capital LLC, despite their intent to appeal.
• Challenges in securing additional financing and partnerships, as evidenced by not achieving 2024 corporate goals in this area due to competitive landscape and financial market changes.
• Dependence on strategic partners like Jazz Pharmaceuticals and BeiGene for the clinical development and commercialization of key drug candidates such as zanidatamab.
• Inherent risks associated with clinical-stage biotechnology development, including successful dose escalation, patient enrollment, and navigating regulatory interactions for pipeline candidates.
• Stock price volatility, which can impact the value of equity compensation and overall investor returns.

Future Outlook

The company aims to continue advancing its diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases. It will continue to invest in employees and culture and anticipates reporting on other corporate sustainability initiatives in the future. The compensation committee will continue to consider feedback from stockholders on executive compensation and market developments for future decisions.

Management Comments

• "We are excited to embrace the latest technology to provide expanded access, improved communication and cost savings for our stockholders and the Company."
• "We believe that Mr. Galbraith's combined role of Chair and Chief Executive Officer enables strong leadership, creates clear accountability, and enhances our ability to communicate our message and strategy clearly and consistently to our stockholders."
• "We believe that our executive compensation program is designed to support our long-term success."
• "We take our say-on-pay vote results seriously and will continue to consider the feedback we receive from stockholders and use such feedback to inform the compensation committee's deliberations and decisions with respect to our executive compensation practices."

Industry Context

Zymeworks operates within the highly competitive clinical-stage biotechnology sector, with a focus on oncology. The company's strategy involves developing multifunctional biotherapeutics and leveraging partnerships for drug advancement and commercialization, a common model in the industry to mitigate R&D costs and risks. The peer group for executive compensation, consisting of publicly traded, pre-commercial biopharmaceutical companies with an emphasis on oncology and similar market capitalizations, reflects the company's positioning within this specialized segment. The challenges in securing financing and partnerships noted in the filing are indicative of broader market dynamics affecting early to mid-stage biotech firms.

Comparison to Industry Standards

• The executive compensation program is benchmarked against a peer group of publicly traded, pre-commercial biopharmaceutical companies, primarily focused on oncology, with market capitalizations generally between $200 million and $1.5 billion, and 100-700 employees, mainly located in North American biotechnology hubs.
• The peer group includes companies such as Adaptimmune Therapeutics plc, Alector, Inc., AnaptysBio, Inc., Atara Biotherapeutics, Inc., Bicycle Therapeutics, C4 Therapeutics, Cogent Biosciences, Gossamer Bio, Inc., IGM Biosciences, Inc., Iteos Therapeutics, Kura Oncology, Inc., MacroGenics, Inc., Mersana Therapeutics, Inc., NGM Biopharmaceuticals, Inc., REGENXBIO Inc., Relay Therapeutics, Repare Therapeutics Inc., Replimune Group, Inc., Sutro Biopharma, Inc., and Xencor.
• The non-employee director compensation program was adjusted in December 2023 and December 2024 to align more closely with the compensation practices of the company's peer group.
• The adoption of stock ownership guidelines for non-management directors (10,000 shares by September 2028) aligns with sound corporate governance practices prevalent in the industry.

Management Changes

Corporate Governance

Legal Proceedings

• On December 13, 2024, the Enforcement Committee of the Autorit des Marchs Financiers (AMF) fined Mr. Oleg Nodelman and EcoR1 Capital LLC 3.0 million and 7.0 million Euros, respectively, for violations of applicable market abuse regulations and failures to comply with reporting obligations for holders that exceed or fall below ownership of five percent of an issuer's equity capital listed on Euronext Paris. Mr. Nodelman and EcoR1 Capital LLC disagree with the AMF's ruling and submitted an appeal in February 2025.

Related Party Transactions

• On June 16, 2023, EcoR1 Capital, LLC (a >5% stockholder) purchased 3,350,000 shares of common stock at $8.12 per share, generating $27.2 million in gross proceeds and $26.2 million in net cash proceeds.
• On December 28, 2023, EcoR1 Capital, LLC purchased 5,086,521 pre-funded warrants for approximately $50 million in a private placement, which included a registration rights agreement and a right for EcoR1 to nominate a board member (leading to Scott Platshon's appointment).
• On June 26, 2025, an amendment to the pre-funded warrants removed an exercise limitation, and EcoR1 net exercised the warrants in full to acquire 5,086,521 shares of common stock. Oleg Nodelman and Scott Platshon, both directors, are affiliated with EcoR1.
• On August 10, 2025, Mr. Gregory A. Ciongoli (a director) purchased 415,000 shares of common stock for $4,988,300 in a private placement.
• All related party transactions were approved pursuant to the company's formal, written policy regarding related person transactions.

Stakeholder Impact

• Shareholders will vote on key governance matters, including director elections, executive compensation, and auditor ratification, directly influencing company oversight and strategic direction.
• Employees are impacted by executive compensation practices designed for attraction, retention, and motivation, as well as participation in various benefit plans (RRSP, 401(k), GPP) and an employee stock purchase plan.
• Patients and customers benefit from the company's continued focus on developing novel biotherapeutics for difficult-to-treat cancers and other serious diseases, exemplified by the FDA accelerated approval of Ziihera.
• Management's compensation structure, including base salary, cash bonuses, and long-term incentives, is designed to align with corporate goals and stockholder interests, with employment agreements providing termination and change-in-control protections.
• Regulatory bodies maintain oversight, as demonstrated by the company's compliance with SEC and Nasdaq requirements, and the AMF's fine against a major shareholder and director highlights ongoing regulatory scrutiny in financial markets.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders on December 30, 2025, to elect directors, vote on executive compensation, and ratify auditors.
• Publish final voting results in a Current Report on Form 8-K promptly following the 2025 Annual Meeting.
• Continue to invest in employees and culture and anticipate reporting on other corporate sustainability initiatives in the future.
• Consider stockholder feedback from the say-on-pay vote for future executive compensation decisions.
• Non-management directors are expected to achieve beneficial ownership of at least 10,000 shares of common stock by September 2028.
• Stockholders wishing to submit proposals for the 2026 annual meeting must do so by July 13, 2026 (Rule 14a-8) or between September 1, 2026, and October 1, 2026 (advance notice procedure).
• Oleg Nodelman and EcoR1 Capital LLC intend to vigorously pursue their appeal against the AMF ruling.

Key Dates

Recommendation

The company demonstrates solid operational progress in its clinical pipeline, including an FDA accelerated approval for a key partnered asset and advancement of its proprietary candidates. This progress is a positive indicator for long-term value creation. However, the reported net loss of $122.7 million and the failure to meet financing and partnership goals for 2024 indicate ongoing financial challenges and a need for future capital. The legal issue involving a major shareholder and director, while appealed, introduces a governance-related overhang. Given the mixed financial performance, continued R&D progress, and governance concerns, a 'hold' recommendation is appropriate, suggesting investors monitor financial improvements and the outcome of the legal appeal while acknowledging the underlying scientific value.

Keywords

Zymeworks, biotechnology, oncology, HER2-positive, zanidatamab, Ziihera, ZW191, ZW251, proxy statement, corporate governance, executive compensation, clinical trials, drug development, FDA approval, stock options, restricted stock units, EcoR1 Capital, KPMG, annual meeting